Chronic Kidney Disease – Landscape & Forecast – Disease Landscape & Forecast (G7)

Chronic kidney disease (CKD) encompasses a set of heterogeneous disorders that gradually damage the kidneys’ structure or function. To manage CKD and delay its progression to end-stage kidney disease, antihypertensive agents and SGLT-2 inhibitors are commonly prescribed. RAAS inhibitors have long been the cornerstone of CKD treatment, while SGLT-2 inhibitors, such as AstraZeneca’s Farxiga and Eli Lilly’s Jardiance, are becoming the standard of care. Bayer’s Kerendia (a mineralocorticoid receptor antagonist) and Novo Nordisk’s semaglutide (a GLP-1 receptor antagonist) are both approved for CKD patients with type 2 diabetes, with Kerendia further being evaluated for potential use in nondiabetic CKD. We expect the CKD therapy market to grow over the 2024-2034 forecast period, driven by an increase in diagnosed CKD cases and emerging therapies such as ProKidney’s rilparencel and various combination therapies. Despite the availability of medications that can delay the progression of CKD, no therapy has been proven to halt or reverse disease progression, leaving a significant unmet need in CKD treatment.

Questions answered

• Does the inclusion of cardiovascular endpoints in clinical trials of CKD therapies confer a competitive advantage?
• What do key opinion leaders consider the advantages and disadvantages of current therapies?
• What is the commercial opportunity for emerging therapies? What are the thoughts of key opinion leaders on emerging therapies?
• What market access and reimbursement challenges will the emerging CKD therapies face in the G7? How will these challenges influence their uptake?

Geography: United States, France, Germany, Italy, Spain, United Kingdom, and Japan

Primary research: Country-specific interviews with thought-leading nephrologists. Supported by survey data collected for this and other Clarivate research.

Epidemiology: Diagnosed prevalence of CKD by country and stage of disease.

Forecast: 10-year, annualized, drug-level sales and patient share of key CKD therapies through 2034, segmented by brands / generics and epidemiological subpopulations.

Drug treatments: Coverage of key current and emerging therapies.

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.